{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:08:12Z","timestamp":1788865692739,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: In advanced high-grade serous tubo-ovarian carcinoma (HGSOC), the chemotherapy response score (CRS) assesses histopathologic response to neoadjuvant chemotherapy (NACT). CRS1 and CRS2 are commonly grouped for similar prognostic outcomes, but whether partial response carries prognostic value and which factors predict pathologic response remain unclear. This multicenter study evaluated predictors of pathologic response and the association of CRS with recurrence-free survival (RFS) and overall survival (OS) after NACT followed by interval debulking surgery (IDS). Materials and Methods: We retrospectively analyzed 157 patients with FIGO stage IIIC-IV HGSOC treated with NACT followed by IDS between 2015 and 2021. Pathologic response was defined as CRS2\u20133 versus CRS1; logistic regression identified predictors of response. Survival was assessed using Kaplan\u2013Meier analysis, and Cox regression evaluated factors associated with RFS and OS. Secondary analyses evaluated the conventional CRS1\u20132 versus CRS3 classification, direct CRS3-versus-CRS2 contrasts, and ordinal trends for RFS and OS. Results: CRS1, CRS2, and CRS3 were observed in 33 (21.0%), 97 (61.8%), and 27 (17.2%) patients, respectively. Median RFS was 10.4, 16.4, and 24.1 months for CRS1, CRS2, and CRS3, respectively (p &lt; 0.001). Median OS was 21.2, 39.1, and 47.0 months, respectively (p &lt; 0.001). In multivariate Cox analysis, CRS2 and CRS3 were independently associated with better RFS (HR 0.36 and 0.24) and OS (HR 0.48 and 0.41) compared with CRS1. In the conventional CRS1\u20132 versus CRS3 model, CRS3 remained associated with lower recurrence risk after multivariate adjustment (HR 0.60; p = 0.042), but not OS (HR 0.74; p = 0.354). Direct CRS3-versus-CRS2 contrasts were nonsignificant for RFS and OS (p = 0.131 and p = 0.628), whereas ordinal trends toward lower hazards were significant for both endpoints (p = 0.001 and p = 0.041). A higher CA-125 decrease rate (OR 1.04) and more than three NACT cycles (OR 4.89) independently predicted pathologic response, whereas FIGO stage IV predicted a lower response (OR 0.15). Conclusions: Partial pathological response (CRS2) was independently associated with improved RFS and OS compared with no or minimal response (CRS1), suggesting that prognostic information is not confined to complete or near-complete pathological response. The conventional CRS1\u20132 versus CRS3 classification remained independently prognostic for RFS after multivariate adjustment but did not reach statistical significance for OS, while direct CRS3-versus-CRS2 contrasts were nonsignificant for both outcomes. Thus, separate evaluation of CRS2 may provide additional RFS stratification within CRS1\u20132. However, the incremental contribution of CRS3 beyond CRS2 could not be established in the present cohort and requires validation in larger cohorts.<\/jats:p>","DOI":"10.3390\/medicina62091688","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:17:37Z","timestamp":1788862657000},"page":"1688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy Response Score and Survival Outcomes After Neoadjuvant Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-6781","authenticated-orcid":false,"given":"Bugra","family":"Oztosun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Mersin City Training and Research Hospital, Mersin 33240, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-8009","authenticated-orcid":false,"given":"Zehra Sucuoglu","family":"Isleyen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Bezmialem Vak\u0131f University, Istanbul 34093, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3613-6482","authenticated-orcid":false,"given":"Zeynep","family":"Alaca Topcu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital, Istanbul 34736, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Atakan","family":"Topcu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Istanbul Medipol University, Istanbul 34718, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Engin","family":"Erdemoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Onkoloji Hospital, Istanbul 34846, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-8558","authenticated-orcid":false,"given":"Melih","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medipol Bahcelievler Hospital, Istanbul 34196, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Mahmut","family":"Gumus","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital, Istanbul 34736, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly Diagnosed and Relapsed Epithelial Ovarian Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up","volume":"34","author":"Harter","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2017517","DOI":"10.1001\/jamanetworkopen.2020.17517","article-title":"Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016","volume":"3","author":"Knisely","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant Chemotherapy versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data from the EORTC 55971 and CHORUS Trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma","volume":"33","author":"Faruqi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/ijgc-2021-003313","article-title":"Survival Impact of Histological Response to Neoadjuvant Chemotherapy According to Number of Cycles in Patients with Advanced Ovarian Cancer","volume":"32","author":"Betrian","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological Chemotherapy Response Score Is Prognostic in Tubo-Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis of Individual Patient Data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1055\/s-0044-1791834","article-title":"Prognostic Significance of Chemotherapy Response Score in Patients Undergoing Interval Debulking Surgery and Attained Complete Cytoreduction for High-Grade Serous Tubal and Ovarian Carcinoma","volume":"14","author":"Santhamma","year":"2025","journal-title":"South Asian J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3802\/jgo.2017.28.e73","article-title":"External Validation of Chemotherapy Response Score System for Histopathological Assessment of Tumor Regression after Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3802\/jgo.2024.35.e73","article-title":"Chemotherapy Response Score No Longer Predicts Survival Outcomes in High-Grade Serous Ovarian Cancer Patients with BRCA Mutation and\/or Maintenance Therapy","volume":"35","author":"Lee","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41416-024-02874-6","article-title":"Germline BRCA1\/2 Status and Chemotherapy Response Score in High-Grade Serous Ovarian Cancer","volume":"131","author":"Morgan","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rodolakis, I., Pergialiotis, V., Liontos, M., Haidopoulos, D., Loutradis, D., Rodolakis, A., Bamias, A., and Thomakos, N. (2023). Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062155"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What Is the Optimal Goal of Primary Cytoreductive Surgery for Bulky Stage IIIC Epithelial Ovarian Carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","article-title":"Prognostic Factors for Complete Debulking in Advanced Ovarian Cancer and Its Impact on Survival. An Exploratory Analysis of a Prospectively Randomized Phase III Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_20","unstructured":"National Comprehensive Cancer Network (2026, June 12). NCCN Clinical Practice Guidelines in Oncology: Ovarian\/Fallopian Tube Cancer\/Primary Peritoneal Cancer. Version 4. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/IGC.0000000000001366","article-title":"Prognostic Value of Pathologic Chemotherapy Response Score in Patients with Ovarian Cancer after Neoadjuvant Chemotherapy","volume":"28","author":"Michaan","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PAS.0000000000001391","article-title":"A 3-Tier Chemotherapy Response Score for Ovarian\/Fallopian Tube\/Peritoneal High-Grade Serous Carcinoma: Is It Clinically Relevant?","volume":"44","author":"Lawson","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"632.e1","DOI":"10.1016\/j.ajog.2014.06.034","article-title":"Prognostic Role and Predictors of Complete Pathologic Response to Neoadjuvant Chemotherapy in Primary Unresectable Ovarian Cancer","volume":"211","author":"Petrillo","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liang, W.-F., Li, H., Wu, J.-Y., Liu, C.-H., Wu, M.-F., and Li, J. (2020). Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.560888"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.3802\/jgo.2023.34.e82","article-title":"Optimal Number of Neoadjuvant Chemotherapy Cycles Prior to Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis of Progression-Free Survival and Overall Survival","volume":"34","author":"Coada","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","article-title":"Complete Cytoreduction after Five or More Cycles of Neo-Adjuvant Chemotherapy Confers a Survival Benefit in Advanced Ovarian Cancer","volume":"44","author":"Phillips","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary Chemotherapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:20:44Z","timestamp":1788862844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091688"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091688","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}